



A **SURESH G KARE** Enterprise

**INDOCO REMEDIES LIMITED**

Regd. Office : Indoco House, 166, CST Road, Santacruz (E), Mumbai 400 098

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2010**

(Rs. In Lacs)

Sr.No	Particulars	Quarter ended 30.06.2010 (Unaudited)	Quarter ended 30.06.2009 (Unaudited)	Year ended 31.03.2010 (Audited)
1	<b>(a) Sales and Income from Operations</b>	<b>11245</b>	9,925	<b>40,231</b>
	Less : Excise Duty	107	91	402
	<b>Net Sales and Income from Operations</b>	<b>11138</b>	9,834	<b>39,829</b>
	<b>(b) Other Operating income</b>	<b>149</b>	229	<b>490</b>
	<b>Total</b>	<b>11287</b>	10,063	<b>40,319</b>
2	<b>Expenditure :</b>			
	(a) (Increase)/Decrease in Finished Goods Stock in trade and work in progress	(407)	(270)	(593)
	(b) Consumption of raw materials	4539	3,663	15,463
	(c) Purchase of traded goods	734	637	2,521
	(d) Employees cost	1476	1,294	5,646
	(e) Depreciation	321	279	1,210
	(f) Research & Development Expenses	192	248	1,022
	(g) Other Expenditure	2846	2,399	10,462
	(h) Total	9701	8,250	35,731
3	<b>Profit from Operations before Other Income, Interest and Exceptional Items</b>	<b>1586</b>	1,813	<b>4,588</b>
4	Other Income	0	8	16
5	<b>Profit before Interest and Exceptional Items</b>	<b>1586</b>	1,821	<b>4,604</b>
6	Interest	65	93	291
7	<b>Profit after Interest but before Exceptional Items</b>	<b>1521</b>	1,728	<b>4,313</b>
8	Exceptional Items	0	-	-
9	<b>Profit from Ordinary Activities before tax</b>	<b>1521</b>	1,728	<b>4,313</b>
10	Tax Expenses - Current	259	195	731
	- Deferred	39	40	126
	- Fringe Benefit Tax	0	-	-
	- Prior Year	0	-	(22)
	- MAT Credit	(259)	(195)	(731)
11	<b>Net Profit from Ordinary Activities after tax</b>	<b>1482</b>	1,688	<b>4,209</b>
12	Extraordinary Items	-	-	-
13	<b>Net Profit for the period</b>	<b>1482</b>	1,688	<b>4,209</b>
14	Paid up Equity Share Capital (Face value Rs.10/- each)	1228.67	1228.67	1,228.67
15	Reserves excluding Revaluation Reserves	-	-	29,822
16	<b>Earning Per Share (EPS) - Not Annualised - Rs.</b>			
	(a) Basic and diluted EPS before Extraordinary Items	12.06	13.74	34.26
	(b) Basic and diluted EPS after Extraordinary Items	12.06	13.74	34.26
17	Public shareholding			
	- No of Shares	48,59,836	47,97,836	48,57,636
	- % of Shareholding	39.56	39.05	39.53
18	Promoters and promoters group shareholding			
	<b>a) Pledged/Encumbered</b>			
	- Number of shares	8,200	8,200	8,200
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.11	0.11	0.11
	- Percentage of shares (as a % of the total share capital of the company)	0.07	0.07	0.07
	<b>b) Non-encumbered</b>			
	- Number of shares	74,18,678	74,80,678	74,20,878
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	99.89	99.89	99.89
	- Percentage of shares (as a % of the total share capital of the company)	60.37	60.88	60.40

Notes :

- The company has only one primary reportable segment of activity, namely, Pharmaceuticals.
- The figures for the previous periods have been regrouped and reclassified, wherever necessary.
- Summary of investor complaints : As on 01.4.2010 :Nil, Received during quarter :3, Resolved:2, Pending as on 30.06.2010 : 1.
- The above results have been recommended by the Audit Committee and taken on record at the meeting of Board of Directors held on 22nd July 2010 and have been subjected to a Limited Review by the Statutory Auditors of the Company.

By Order of the Board

Place : Mumbai  
Date : July 22, 2010

**Suresh G. Kare**  
Chairman & Managing Director